Mizuho analyst Irina Koffler sees a favorable risk/reward for Supernus Pharmaceuticals into this month’s adolescent data release after reviewing the SPN-812 pediatric data with a psychiatrist and management. The analyst raised her price target for the shares to $63 from $61 and reiterates a Buy rating on Supernus.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.